Clinical Trial Update: A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating preoperative MM-121 with Paclitaxel in HER2-negative breast cancer completed; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• MM-121 (seribantumab) (seribantumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients | Phase 2 | Status: COMPLETED | Results posted: 2016-03-14